InnoCare Pharma

Concentration Risk And China's Regulatory Scrutiny Will Bar Pipeline Progress

AnalystLowTarget

Not Invested

Community Contributor

Published

07 Aug 25

AnalystLowTarget's Fair Value

HK$8.20

129.5% overvalued

04 Sep

HK$18.81

180.3%

0.5%

180.3%

0.5%

You can edit this narrative until Aug 7 10:35 PM. Then, changes will post as Updates.

Author's Valuation

HK$8.2129.5% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

HK$8.2

129.5% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

22.85%

Biotech revenue growth rate

8.70%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.96%

Calculation

CN¥330.70m

Earnings '28

27.02x

PE Ratio '28

CN¥8.94b

Market Cap '28

CN¥8.94b

Market Cap '28

975.18m

No. shares '28

CN¥9.16

Share Price '28

CN¥9.16 Share Price '28

Discounted to 2025 @ 6.89% p.a.

CN¥7.50

Fair Value '25

CN¥7.50 Fair Value '25

Converted to HKD @ 1.0927 CNY/HKD Exchange Rate

HK$8.20

Fair Value '25